[The use of the alpha-glucosidase inhibitor acarbose for the treatment of type-2 diabetes mellitus in secondary sulfanilamide resistance].

Efficacy was studied of acarbose in patients with type II diabetes mellitus during the development of secondary sulfamide resistance. 63 patients were evaluated. Studies were made involving glycemia on an empty stomach, postprandial glycemia and 24-h glucosuria in order that we might learn about the above drug's efficacy. High confidence level decrease in postprandial glycemia was recorded as was significant reduction in diurnal glucosuria.